Using the CRISPR/Cas9 genome editing system, researchers from the University of Texas Southwestern Medical Center were able to prevent Duchenne muscular dystrophy in a mouse model of the disease. The researchers aimed to correct the nonsense mutation in exon 23 of the Dmd gene that the mdx mouse model of Duchenne muscle dystrophy harbors. Sequencing of the mice revealed that CRISPR/Cas9–mediated germline editing led to genetically mosaic corrected mice, which had between 2 percent and 100 percent correction of the Dmd gene.
The FDA has approved Exact Sciences' Cologuard colorectal cancer screening test, while the CMS issued a proposed national coverage determination for the test. The test analyzes hemoglobin, multiple DNA methylation biomarkers, mutations in the KRAS gene, and the total amount of DNA in stool samples. CMS is proposing to cover testing using Cologuard once every three years for Medicare beneficiaries who are between the ages of 50 and 85, are asymptomatic for colorectal disease, and are at average risk for developing the disease.
The National Institute of General Medical Sciences will provide up to $2 million per year to renew funding for each of the National Centers for Systems Biology, pending approval of renewal applications. NIGMS currently funds 12 systems biology centers at institutions across the US that use a wide range of molecular, cellular, biochemical, behavioral, and other approaches to study complex biological phenomena. The systems biology centers program is currently under evaluation, NIGMS said, so it is not currently offering awards to fund new centers.
This online seminar will provide an overview of new tools for screening stem cells — in particular, the use of RNA detection probes to detect pluripotency gene expression in live embryonic and induced pluripotent stem cells by fluorescence microscopy without the need for manipulation of the cells.